Craig Portell headshot
CP

Craig Anthony Portell

Associate Professor
Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
Emily Couric Clinical Cancer Center
1335 Lee St
Charlottesville, Virginia 22903
Education
Saint Louis University 2006, MD
Residency, Loyola University- Chicago (Internal Medicine) 2009
Fellowship, Cleveland Clinic - Taussig Cancer Institute (Hematology and Medical Oncology) 2013
Biography

Dr. Portell holds a clinical faculty appointment in medicine in the Division of Hematology/Oncology at the University of Virginia. He practices at the Emily Couric Clinical Cancer Center in Charlottesville and serves as an inpatient hematologist at UVA Health System. He attended medical school at Saint Louis University in St. Louis, MO, and completed internal medicine residency at Loyola University Hospital near Chicago, IL. He completed fellowship in Hematology and Medical Oncology at the Cleveland Clinic, Cleveland, OH, in 2013, where he was chief fellow from 2012-2013.

Dr. Portell joined UVA in 2013. He lives with his wife and enjoys playing with his small dog, exercising, traveling and exploring new cuisines.

A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects with Hematological Malignancies
Source: VELOSBIO INC.
December 10, 2020 – December 09, 2023
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone
Source: ECOG-ACRIN Cancer Research Group
January 15, 2018 – January 14, 2023
MD-INMD-HO - Portell - Novartis - CTL019E2202
Source: Novartis Pharmaceuticals Corporation
August 01, 2018 – December 31, 2022
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
Source: Alpha Oncology, Inc.
September 06, 2019 – September 05, 2022
MD-INMD-HO Portell Xenxor Xmab 13676-01
Source: Xencor, Inc.
August 16, 2018 – August 15, 2022
A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Source: ECOG-ACRIN Cancer Research Group
June 14, 2019 – June 13, 2022
A RANDOMIZED PHASE III STUDY OF IBRUTINIB PLUS OBINUTUZUMAB VERSUS IBRUTINIB PLUS VENETOCLAX AND OBINUTUZUMAB IN UNTREATED OLDER PATIENTS (¿ 70 YEARS OF AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Source: Alliance for Clinical Trials in Oncology Foundatio
June 14, 2019 – June 13, 2022
Characterization of poor-risk relapsed NonHodgkin Lymphoma subtypes for precision medicine
Source: Emory University
January 16, 2020 – May 29, 2022
Portell Belgene BGB-3111-304
Source: BeiGene, Ltd.
May 18, 2018 – May 17, 2022
MD-INMD Multi-Institution Phase l/lb study of Ibrutinib with ABT-199 in relapsed/refractory mantle cell lymphoma
Source: AbbVie Inc.
July 21, 2015 – April 03, 2022
Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma as Front Line Therapy
Source: Alpha Oncology, Inc.
February 22, 2018 – February 21, 2022
MD-INMD A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lympocytic Lymphoma
Source: Infinity Pharmaceuticals, Inc.
July 28, 2014 – December 31, 2021
PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin¿s Lymphoma
Source: Acerta Pharma LLC
October 02, 2018 – October 01, 2021
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Source: Alpha Oncology, Inc.
September 04, 2018 – September 03, 2021
MD-INMD-HO A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients with Chronic Lymphocytic Leukemia
Source: Brigham & Women's Hospital, Inc.
December 18, 2014 – May 16, 2021
MD-INMD-HO A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07_Verastem
Source: Verastem, Inc.
January 01, 2017 – December 31, 2019
MD-INMD A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lympocytic Lymphoma
Source: Verastem, Inc.
January 01, 2017 – December 31, 2019
MD-INMD-HO A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07
Source: Infinity Pharmaceuticals, Inc.
November 03, 2014 – August 28, 2019
MD-INMD-HO Multi-Institution Phase I/Ib Studt of Ibrutinib with APT-199 in Relapsed/Refractory Mantle Cell Lymphoma
Source: Lymphoma Research Foundation
January 15, 2015 – December 31, 2017
MD-INMD Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients with Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma and Evaluation of Corrected QT (QTc) Interval and Pharmacokinetics in Pati
Source: Alpha Oncology, Inc.
August 12, 2014 – April 10, 2017
  • 2015-2017 Lymphoma Research Foundation Lymphoma Clinical Research Mentoring Program Scholar